Abstract
Introduction Tumor angiogenesis and metastasis
Angiogenesis, the formation of new blood vessels from pre-existing blood vessels, is a fundamental process occurring during tumor progression [1, 2] . Like normal tissues, tumors require an adequate supply of oxygen, metabolites and an effective way to remove waste products. Gaining access to the host vascular system and generation of tumor blood supply is the rate-limiting step in tumor progression. Angiogenesis depends on the balance between pro-angiogenic molecules (VEGF, FGF, EGF, etc.) and antiangiogenic molecules (angiostatin, endostatin, etc.) [3, 4] . The fact that tumors are dependent on blood supply has inspired many scientists to search for antiangiogenic molecules, and to design anti-angiogenic strategies for cancer treatment and prevention of cancer recurrence and metastasis [5] [6] [7] .
Tumor angiogenesis differs significantly from physiological angiogenesis. The differences include aberrant vascular structure, altered endothelial cellpericyte interactions, abnormal blood flow, increased permeability and delayed maturation [2, 8, 9] . Most tumors start growing as avascular nodules (dormant) until they reach a steady-state level of proliferating and apoptotic cells. Angiogenesis begins with perivascular detachment and vessel dilation, followed by angiogenic sprouting, new vessel formation and maturation, and the recruitment of perivascular cells. Blood-vessel formation continues as the tumor grows, feeding on hypoxic and necrotic areas of the tumor for essential nutrients and oxygen.
Cancer cells spread throughout the body by metastasis [10, 11] . Both genetic and epigenetic changes contribute to cancer cells metastasis within a primary tumor. Metastasis occurs through several steps. First, cancer cells lose E-cadherin-dependent intercellular adhesions, acquire a migratory phenotype, detach from neighboring cells, penetrate the basement membrane and invade the interstitial matrix [12] . Second, tumor cells penetrate into blood vessels and lymphatic vessels and enter the circulatory system, a process called intravasation [13] . After reaching the bloodstream, tumor cells often adhere to platelets and leukocytes, forming emboli that stop in the microcirculation of target organs more easily than individual tumor cells [14] . Finally, metastatic cells exit the bloodstream (extravasation) and undergo expansive growth within the parenchyma of the target organ.
Role of integrin during tumor progression
Molecules regulating angiogenesis include growth factor receptors, tyrosine kinase receptors, G-proteincoupled receptors for angiogenesis modulating proteins, and integrins, a family of adhesion molecules consisting of two non-covalently bound transmembrane subunits ( and ) [2] [3] [4] . Increasing amounts of evidence now imply that integrin signaling plays a key role in tumor angiogenesis and metastasis [15] [16] [17] .
Efficient tumor invasion requires partial degradation of the extracellular matrix (ECM) at the invasion front. The matrix metalloproteinases (MMPs) are the major proteases involved in remodeling the ECM [12] . The v 3 integrin, which binds to ArginineGlycine-Aspartic acid (RGD)-containing components of the interstitial matrix, such as vitronectin, fibronectin and thrombospondin, is significantly upregulated on endothelium during angiogenesis but not in quiescent endothelium [17] [18] [19] . The special role of integrin v 3 in tumor invasion and metastasis arises from its ability to recruit and activate MMP-2 and plasmin, which degrade components of the basement membrane and interstitial matrix [20] . Once integrin v 3 is expressed, angiogenesis depends on it as antagonists of integrin v 3 (antibodies, peptides and peptidomimetics) can inhibit tumor angiogenesis, tumor growth and metastasis in vivo [15, 16] . Research has also shown that tumor expression of integrin α v β 3 correlates well with tumor progression in several malignancies such as melanoma [21] , glioma [22] , ovarian [23] and breast cancer [24, 25] .
Integrin α v β 3 as the imaging target
Conventional imaging modalities that detect anatomical and functional changes of tumor vascularity during angiogenesis, tumor growth and upon anti-angiogenic treatment provide little or no information regarding the specific molecular markers on newly formed blood vessels, tumor cells and the molecular changes upon therapy. Molecular imaging takes advantage of traditional diagnostic imaging techniques and introduces molecular imaging probes to determine the expression of indicative molecular markers of the tumor development at different stages [26] [27] [28] .
For a targeting approach aimed at monitoring tumor angiogenesis and metastasis, the sufficient level of accessible tumor specific targets is a prerequisite for the lesion to be detectable and delineated from the background by imaging technologies. Integrin v 3 serves as an excellent molecular marker for tumor angiogenesis and metastasis imaging. Interactions between vascular cells and ECMs are involved in multiple steps of angiogenesis [15, 17, 19] . Adhesion receptors of the integrin family are responsible for a wide range of cell-ECM and cell-cell interactions [29, 30] . Each integrin molecule consists of noncovalently associated α and β subunits, both type I membrane proteins with large extracellular segments that pair to create heterodimers with distinct adhesive capabilities [31, 32] . In mammals, 18 α and 8 β subunits assemble into 24 different receptors. The function of integrins during angiogenesis has been studied most extensively with α v β 3 , which is not readily detectable in quiescent vessels but becomes highly expressed in angiogenic vessels [15, 16] . Integrins expressed on endothelial cells modulate cell migration and survival during angiogenesis while integrins expressed on carcinoma cells potentiate metastasis by facilitating invasion and movement across blood vessels. Inhibition of α v integrin activity by monoclonal antibodies (mAbs), cyclic RGD peptide antagonists, and peptidomimetics has been shown to induce endothelial cell apoptosis [33] , to inhibit angiogenesis [16] , and to increase endothelial monolayer permeability [34] .
The ability to non-invasively visualize and quantify integrin v 3 expression level will provide new opportunities to document tumor (tumor cells and sprouting tumor vasculature) integrin expression, to more appropriately select patients for anti-integrin treatment and to monitor treatment efficacy in integrin-positive patients.
Non-radionuclide imaging of integrin v 3 expression
Over the last several years, research on integrintargeted molecular imaging has flourished. Contrastenhanced ultrasound using microbubbles targeting vintegrins expressed on the neovascular endothelium has been used to image tumor integrin status in addition to tumor microvascular blood volume and blood velocity, which can be easily detected with nontargeted microbubbles [35] . In an animal model, Sipkins et al. recently demonstrated the use of antibody-coated paramagnetic liposomes for MRI imaging of integrin α v β 3 expression [36] . However, due to the unfavorable physical characteristics of mAbs (vascularization requirements and barriers to antibody penetration, as well as intratumoral pressure) and low sensitivity of MRI, targeted MR imaging faces significant obstacles in providing a robust platform for tumor integrin assessment.
Recently, we and others have shown that nearinfrared (NIR) fluorescent dye Cy5.5 conjugated cyclic RGD peptide could be used to visualize subcutaneously inoculated integrin-positive tumors [22, 37] . Since the major drawback of optical imaging is the limited penetration of light through tissue and skin, it has primarily been directed towards near surface lesions. Even though optical imaging may not be easily translated to human studies, NIR approach provides opportunities for rapid and cost-effective preclinical evaluation in small animal models before the more costly radionuclide-based imaging studies since in the NIR region (700 -900 nm), the absorbance spectra for all biomolecules reach minima which provides a clear window for in vivo optical imaging [38] .
PET imaging of integrin v 3 expression
To date, most of the studies have been focused on developing suitably radio-labeled RGD peptide antagonists of α v -integrin as radiopharmaceuticals or molecular imaging probes for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) [24, [39] [40] [41] . For early lesion detection, acquisition of higher count statistics is particularly valuable for detecting the fewest possible cells per unit volume with the least amount of radioactivity. Due to the higher sensitivity of PET (10 [18] . The essential RGD sequence in this restrained conformation is well suited for development of high affinity and specific molecular imaging probes targeting integrin v 3 . The current status of RGD-based PET probe development is reviewed in detail here.
F-labeled RGD peptides
Monomeric RGD peptide c(RGDyV) was first labeled by Haubner et al. with 125 I [44] . This relatively lipophilic compound had rapid tumor washout and unfavorable hepatobiliary excretion. The resulting high liver and intestinal activity accumulation limited its further application. Glycosylation on the lysine side chain of a similar RGD peptide c(RGDyK) decreased the lipophilicity and consequently the hepatic uptake [45] . Another glycopeptide based on c(RGDfK) was then labeled with 18 F via 2-[
18 F]fluoropropionate prosthetic group and the resulting [
18 F]galacto-RGD (Figure 1 ) exhibited integrin v 3 specific tumor uptake in integrin-positive M21 melanoma xenograft model [41, 46, 47] . Initial clinical trials in healthy volunteers and a limited number of cancer patients revealed that this tracer can safely be administered to patients and is capable of delineating certain lesions that are integrin-positive [41] . Despite the initial success of this tracer in preclinical and clinical studies, several key issues remain to be resolved: 1) Tumor targeting efficacy. As a monomeric RGD peptide tracer, [ 18 F]galacto-RGD has relatively low integrin binding affinity and thus only moderate tumor SUV values; 2) Pharmacokinetics. Although glycosylation improved the pharmacokinetic behavior of an otherwise hydrophobic RGD peptide tracer, prominent activity accumulation in the kidneys, spleen, liver, and intestines was still observed in both preclinical animal models and human studies; 3) Quantification of integrin expression level. It is not clear whether the tumor contrast from [ Sutcliffe-Goulden et al. also labeled a linear RGD peptide with 18 F via solid-phase synthesis [48] . Unfortunately, low avidity and low metabolic stability of the linear RGD peptide failed to provide tumor contrast. Moreover, this seemingly facile solid-phase 18 F-labeling method is amenable to linear peptides but it would be difficult to apply to cyclic RGD peptides. RGD peptides have also been labeled with 18 F through electrophilic substitution method [49] . The direct fluorination strategy resulted in multiple products which are difficult to purify by HPLC. The low specific activity of the carrier-added product, in particular, makes such tracers unsuitable for integrin imaging.
During the last few years, we have been focusing on the development of RGD-based probes for multimodality imaging of tumor integrin expression, including PET ( 18 Instead of introducing an amino sugar moiety to increase the hydrophilicity [41, 46, 47] , we incorporated an amphiphilic poly(ethylene glycol) linker (PEG, MW = 3,400) to improve the pharmacokinetics [51, 52] . PEGylation significantly prolonged tumor retention without compromising the desirabe rapid clearance of radioactivity from liver and kidneys (Figure 3) . Additionally, decreased biliary excretion minimized intestinal retention of the activity and increased tumor-to-background ratios. However, PEGylation also reduced the receptor binding affinity of the RGD peptide. The overall effect is that the tumor uptake is comparable to what is observed for the unmodified monomeric RGD peptide but with somewhat improved pharmacokinetics. Another disadvantage is that PEG is not a single species but rather a collection of molecules with an average molecular weight of 3,400 Da, which makes complete characterization of the tracer more difficult. Since c(RGDyK) in bent conformation has been optimized to fit into the deep cleft between the and units of integrin v 3 , it is very unlikely that one can further improve integrin affinity and selectivity of the monomeric RGD peptide by fine-tuning the pentapeptide configuration [18, 30] . We thus applied polyvalency effect to develop dimeric and multimeric RGD peptides, with repeating cyclic pentapeptide units connected by glutamates. The dimeric RGD peptide E[c(RGDyK)] 2 with almost one order of magnitude higher binding affinity than the corresponding monomer c(RGDyK) was then labeled with 18 (Figure 4) showed predominant renal excretion and almost twice as much tumor uptake in the same animal model as compared to the monomeric tracer [
18 F]FB-c(RGDyK). The synergistic effect of polyvalency and improved pharmacokinetics may be responsible for the excellent imaging characteristics of the dimeric RGD peptide tracer [55] . Furthermore, we have performed dynamic scans in several tumor xenograft models, including U87MG glioma, C6 rat glioma, MDA-MB-435 breast cancer, PC-3 prostate cancer, NCI-H1975 and A549 non-small cell lung cancers ( Figure 5 ). Graphical analysis of the PET data (Logan plot [56] ) which plots normalized integrated activity in the tumor vs. the normalized integrated activity in the muscle is shown in Figure 6 . The graph becomes linear after 25-30 min post-injection (p.i.) where the slope represents distribution volume ratio (DVR). The binding potential (BP) which equals the concentration ratio of bond and free radioligand were 29.5, 17.5, 5.8, 4.1, 3.8, and 1.9, respectively (our unpublished data). (Figure 8) . This is the first report that one can quantify integrin expression in vivo by non-invasive PET imaging, which provides the basis for precise documentation of tumor integrin levels without biopsy. Estimation of human radiation dosimetry from the mouse and rat biodistribution data found that the effective dose for an [ [58] . PET imaging of tumors with low doses of 64 Culabeled RGD peptides could also be utilized to determine individual radiation dosimetry prior to therapy with either high dose 64 Cu-or 67 Cu-labeled RGD peptides. 64 Cu labeling is also fairly straightforward and amenable for kit formulation.
We initially labeled the DOTA-c(RGDyK) conjugate with 64 Cu for breast cancer imaging ( Figure  9) . The radiotracer showed intermediate tumor uptake but also prominent liver and kidney retention [24] . The PEGylated analog, 64 Cu-DOTA-PEG-c(RGDyK), on the other hand, had significantly reduced hepatic activity accumulation, as compared with 64 Cu-DOTAc(RGDyK) [40] . The PEGylated tracer had higher renal uptake than 64 Cu-DOTA-c(RGDyK) at early time points but more rapid clearance as time elapsed. Although introduction of PEG at the lysine side chain amino group somewhat reduced the integrin binding affinity of the RGD peptide, the tumor activity accumulation was virtually unaltered. In spite of the high tumor contrast and favorable in vivo kinetics, the sub-optimal tumor uptake and retention of the PEGylated tracer limited its further application for receptor radionuclide therapy. We have also labeled dimeric RGD peptides with 64 Cu and 86 Y and tested their tumor targeting efficacy in murine xenograft models. At all time points, activity accumulation of 64 Cu-DOTA-E[c(RGDyK)] 2 in tumors was significantly higher than that of the DPhe analog [25] . Liver uptake of the D-Tyr derivative c(RGDyK) was lower than the D-Phe derivative c(RGDfK) at early time points but the difference became marginal over time. Overall, 64 Cu-DOTA-E[c(RGDyK)] 2 yielded better PET images in orthotopic MDA-MB-435 bearing mice than did 64 Cu-DOTA-E[c(RGDfK)] 2 , most likely due to the increased hydrophilicity of the D-Tyr. Both dimeric peptides showed better tumor retention than the previously tested monomeric RGD counterparts, presumably because of bivalency and increase in apparent molecular size. We have also demonstrated that the tumor uptake can be efficiently blocked by injection of unlabeled RGD peptide (Figure 10 ) [25] . PEGylated RGD dimer 64 Cu-DOTA-PEG-E[c(RGDyK)] 2 had similar blood clearance, more rapid renal clearance, and significantly reduced hepatic uptake compared with 64 Cu-DOTA-E[c(RGDyK)] 2 [53] . However, tumor uptake was also lowered due to the fact that the PEGylated RGD dimer had lower receptor binding affinity than the dimeric RGD peptide. Rapid tumor localization with relatively low normal tissue uptake outside the gut makes 64 Cu-DOTA-PEG-E[c(RGDyK)] 2 a promising agent for tumor imaging. One striking observation is that PEGylated dimeric RGD peptide tracer accumulated more specifically in both primary and metastatic lung tumor lesions than FDG, which only delineates the primary tumor but none of the metastatic sites (data not shown) since FDG uptake is not tumor specific which gives very high background in the heart and the abdomen (Figure 11) . However, the significance of this finding may be slightly diluted by the fact that the magnitude of tumor uptake is too low (less than 3 %ID/g) for peptide receptor radiotherapy (PRRT) applications [53] . The RGD tetramer showed significantly higher integrin binding affinity than the corresponding monoand dimeric RGD analogs (Figure 13) . The radiolabeled peptide showed rapid blood clearance and predominant renal excretion. Tumor uptake was rapid and high, and the tumor washout was slow (9.93 ± 1.05 %ID/g at 30 min p.i. and 4.56 ± 0.51 %ID/g at 24 h p.i.). This tracer was also metabolically stable. Noninvasive microPET imaging studies showed significant receptor-mediated tumor uptake and good contrast in tumor mice. The high integrin avidity and favorable biokinetics make 64 Cu-DOTA-E{E[c(RGDfK)] 2 } 2 a promising agent for peptide receptor radionuclide imaging as well as radiotherapy of integrin-positive tumors. 
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Conclusion and future perspective
Significant advances have been achieved in developing PET probes for imaging tumor integrin α v β 3 expression. 18 F and 64 Cu labeled RGD-based tracers exhibited highly sensitive and integrin α v β 3 specific tumor uptake, desirable pharmacokinetics, pharmacodynamics and metabolic stability, as well as high tumor activity accumulation. We have recently demonstrated that graphical analysis of non-invasive PET imaging data allows quantification of tumor integrin expression level in vivo. All of the above features are crucial for clinical application of integrintargeted early lesion detection and targeted internal radiotherapy.
The dimeric RGD peptide tracer [ 18 F]FB-E[c(RGDyK)] 2 , which can be used to quantify integrin expression level, has high integrin v 3 avidity in vitro and integrin specific tumor uptake in vivo [25, 53, 54, 60] . Human dosimetry estimation based on animal biodistribution data predicts that this tracer could be safely used in human, which makes it a promising lead candidate for clinical translation.
The tetrameric RGD peptide E{E[c(RGDfK)] 2 } 2, when labeled with 64 Cu through DOTA chelator, showed very high integrin avidity and good metabolic stability in the blood stream. [59] The overall high and prolonged tumor retention and rapid liver and kidney clearance result in good tumor to normal organ ratios, which not only makes it suitable for early lesion Lu [61] [62] [63] [64] , the same conjugates developed in this project will have widespread applications for both radionuclide imaging and receptor-mediated internal radiotherapy.
Tumor integrin α v β 3 expression imaging is given as an example here to demonstrate how molecular imaging can provide a robust platform for understanding the mechanisms of tumor angiogensis and evaluating the efficacy of novel anti-angiogenic therapies. Further progress is needed to improve the sensitivity and resolution of molecular imaging technologies and to develop optimal molecular imaging probes as surrogate markers to pinpoint and monitor specific molecular and cellular actions of angiogenesis inhibitors As the molecular imaging probes get more and more specific which leads to visible signal only in the tumor or other targeted tissue, anatomical/functional imaging techniques is needed to identify the exact location of the signal. Multimodality molecular imaging techniques such as PET/CT (already in clinic) and SEPCT/CT are expected to play a major role in molecular imaging in the near future. 
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